培美曲塞联合吉非替尼治疗EGFR突变阳性晚期非小细胞肺癌的效果及对TPX2、GASP-1的影响

Effect of pemetrexed combined with gefitinib in the treatment of EGFR mutation positive advanced non-small-cell lung cancer and its influences on TPX2 and GASP-1

目的分析培美曲塞联合吉非替尼治疗表皮生长因子受体(EGFR)突变阳性晚期非小细胞肺癌(NSCLC)的效果。方法选取2019年4月至2022年4月收治的90例EGFR突变阳性晚期NSCLC患者为研究对象,根据随机数字表法将其分为对照组(n=45,吉非替尼)和研究组(n=45,吉非替尼+培美曲塞)。比较两组的治疗效果。结果研究组的疾病控制总有效率显著高于对照组,差异具有统计学意义(P<0.05)。治疗后,研究组的EGFR、Xklp2靶蛋白(TPX2)、G蛋白偶联受体相关分选蛋白-1(GASP-1)、基质金属蛋白酶抑制剂-1(TIMP-1)、基质金属蛋白酶-9(MMP-9)水平低于对照组,差异具有统计学意义(P<0.05)。治疗后,研究组的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组,差异具有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论培美曲塞联合吉非替尼治疗EGFR突变阳性晚期NSCLC患者能够通过改善实验室指标、提高机体免疫力来提高临床疗效,值得推广应用。

Objective To analyze the effect of pemetrexed combined with gefitinib in the treatment of epidermal growth factor receptor(EGFR)mutation positive advanced non-small-cell lung cancer(NSCLC).Methods A total of 90 patients with EGFR mutation positive advanced NSCLC admitted from April 2019 to April 2022 were selected as the research objects.According to the random number table method,the patients were divided into control group(n=45,gefitinib)and study group(n=45,gefitinib+pemetrexed).The therapeutic effects of the two groups were compared.Results The total effective rate of disease control in the study group was significantly higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the EGFR,targeting protein for Xenopus kinesin-like protein 2(TPX2),G protein-coupled receptor associated sorting protein-1(GASP-1),tissue inhibitor of metalloprotease-1(TIMP-1)and matrix metalloproteinase-9(MMP-9)levels in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the study group were higher than those in the control group,and the CD8^(+)was lower than that in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Pemetrexed combined with gefitinib in the treatment of EGFR mutation positive advanced NSCLC patients can enhance the clinical efficacy by improve laboratory indicators and enhance immunity,which is worthy of promotion and application.